<DOC>
	<DOCNO>NCT00174863</DOCNO>
	<brief_summary>To evaluate efficacy SR31747 give 75 125mg per day versus placebo androgen prostate cancer patient without distant metastasis Time Clinical progression main objective PSA parameter , Tumor response , survival , safety , Tumor-related symptom deterioration Quality Life , PK analysis secondary objective</brief_summary>
	<brief_title>Evaluation SR 31747A Versus Placebo Androgen-Independent Non Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Prior confirm histological diagnosis prostatic carcinoma . Rising PSA receive hormonal therapy surgical castration define 2 sequential increase previous low reference value within past 12 month ; PSA must least 4ng/ml time study entry . No distant metastasis evidence bone scan ( + center XRay MRI ) , spiral thoracoabdominopelvic CT scan . Effective castration throughout study . Any prior antiandrogen therapy stop document continued elevation PSA 4 week cessation flutamide ( 6 week bicalutamide ) . Serum testosterone level &lt; 50ng/dL time progression throughout study . Age &gt; = 18 year . Extensive metabolizer CYP2D6 genotyping . Karnofsky Performance Status &gt; = 70 % life expectancy &gt; 6 month . Adequate hematological , renal liver function . Signed write informed consent Poor metabolizers CYP2D6 genotyping . Prior palliative radiotherapy prior chemotherapy experimental therapy . More one line prior anticancer treatment estrogen ( estrogen estramustine ) discontinue least 4 week study entry . Concomitant administration biphosphonate chronic corticosteroid . Presence progressive symptom adequately control non opioid medication Concomitant use medication know cytochrome P450 2D6 inhibitor list protocol appendice Previous malignancy except diseasefree interval least 5 year except curatively treat nonmelanoma skin cancer Other serious illness medical condition , would permit patient manage accord protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
</DOC>